Bioatla Inc (BCAB) - Total Liabilities
Based on the latest financial reports, Bioatla Inc (BCAB) has total liabilities worth $45.88 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioatla Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Bioatla Inc's total liabilities have evolved over time, based on quarterly financial data. See Bioatla Inc (BCAB) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Bioatla Inc Competitors by Total Liabilities
The table below lists competitors of Bioatla Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Moolec Science SA Ordinary Shares
NASDAQ:MLEC
|
USA | $28.58 Million |
|
Gafisa S.A
SA:GFSA3
|
Brazil | R$3.20 Billion |
|
Rectifier Technologies Ltd
AU:RFT
|
Australia | AU$12.85 Million |
|
Nigbas Nigde Beton Sanayi ve Ticaret AS
IS:NIBAS
|
Turkey | TL161.14 Million |
|
GEOTRANS S.A. ZY -10
F:5Z4
|
Germany | €4.08 Million |
|
Tartana Minerals Ltd
AU:TAT
|
Australia | AU$7.54 Million |
|
Aptorum Group Ltd Class A
NASDAQ:APM
|
USA | $4.90 Million |
|
K.C. Metalsheet Public Company Limited
BK:KCM
|
Thailand | ฿219.68 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Bioatla Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bioatla Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioatla Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioatla Inc (2018–2025)
The table below shows the annual total liabilities of Bioatla Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.02 Million | +31.08% |
| 2024-12-31 | $38.16 Million | -22.11% |
| 2023-12-31 | $48.99 Million | +7.91% |
| 2022-12-31 | $45.40 Million | +4.12% |
| 2021-12-31 | $43.60 Million | +24.71% |
| 2020-12-31 | $34.96 Million | -46.50% |
| 2019-12-31 | $65.35 Million | +44.95% |
| 2018-12-31 | $45.08 Million | -- |
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); a… Read more